Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
Sponsor: Baxalta now part of Shire
This PHASE2 trial investigates Immune Thrombocytopenic Purpura (ITP) and is currently completed. Baxalta now part of Shire leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Nov 2017 — Feb 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE2
First recorded
Jan 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brno, Czechia , Debrecen, Hungary , Giessen, Germany , Győr, Hungary , Halle, Germany , Hradec Králové, Czechia , Lodz, Poland , Olomouc, Czechia , Prague, Czechia , Szeged, Hungary and 1 more location